Westerkirk Capital’s Amgen AMGN Stock Holding History

Westerkirk Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,370	Closed	-$669K	–	237
2025 Q3	$669K	Buy	+2,370	New	+$687K	0.08%	174

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Westerkirk Capital's AMGN Position: Q4 2025 in Review

Westerkirk Capital sold out of Amgen (AMGN) in Q4 2025, closing a stake of 2,370 shares — an estimated $669K sold.

Westerkirk Capital first reported a position in AMGN in Q3 2025 and held it in 1 quarter. The position peaked at $669K in Q3 2025. 3,092 funds tracked by Wall St. Rank hold AMGN as of Q4 2025.

Westerkirk Capital reported no remaining Amgen position as of Q4 2025 after selling out during the quarter.
Westerkirk Capital sold 2,370 Amgen shares in Q4 2025, an estimated $669K.
Westerkirk Capital first reported a position in Amgen in Q3 2025 and held it in 1 quarter.
Westerkirk Capital's Amgen position peaked at $669K in Q3 2025.
3,092 funds tracked by Wall St. Rank held Amgen as of Q4 2025.

Based on Westerkirk Capital's 13F filing for Q4 2025, filed 11 Feb 2026.